title: Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments.
abstract: Three high-concentration vitamin D3 ointments are currently available in Japan for the treatment of psoriasis. The aim of the present study is to investigate the efficacy of high-concentration tacalcitol in patients with psoriasis vulgaris who have already been treated with another high-concentration vitamin D3 ointment, calcipotriol or maxacalcitol. The psoriasis area and severity index score was improved in more than half the patients after changing to the tacalcitol ointment. Many patients treated with maxacalcitol once a day achieved greater clinical improvement by changing to high-concentration tacalcitol. In contrast, some patients who had responded to a high-concentration tacalcitol ointment showed exacerbation after changing to maxacalcitol once a day. Interviews with 50 patients (including the 34 patients enrolled in the present study) indicated that high-concentration tacalcitol ointment was an acceptable therapy in terms of the number of daily applications and drug cost. The results of this clinical study suggest that high-concentration tacalcitol ointment meets the preference of many patients who wish to use an ointment once a day.
authors.affiliation: Department of Dermatology, Gunma University Graduate School of Medicine, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Syuto
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Ishibuchi
authors.forename: Yoko
authors.initials: Y
authors.lastname: Sogabe
authors.forename: Yoko
authors.initials: Y
authors.lastname: Yokoyama
authors.forename: Osamu
authors.initials: O
authors.lastname: Ishikawa
mesh_terms: D002117:Calcitriol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D004100:Dihydroxycholecalciferols / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D009824:Ointments; D010342:Patient Acceptance of Health Care; D011306:Prescription Fees; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D004100:Dihydroxycholecalciferols; D009824:Ointments; C055085:calcipotriene; C023850:1 alpha,24-dihydroxyvitamin D3; D002117:Calcitriol; C051883:maxacalcitol